

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

XtalPi

晶泰科技

XtalPi Holdings Limited

晶泰控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2228)

VOLUNTARY ANNOUNCEMENT

XTALPI'S AI INNOVATIVE R&D PLATFORM SUCCESSFULLY DEVELOPED NEW MOLECULES “GEMINI” FOR HAIR GROWTH AND OBTAINED KEY INTERNATIONAL CERTIFICATES

This announcement is made by XtalPi Holdings Limited (the “**Company**” or “**XtalPi**”, together with its subsidiaries, the “**Group**”) on a voluntary basis. The purpose of this announcement is to keep the shareholders and potential investors of the Company informed of the latest business development of the Group.

According to the population projections of the United Nations and iResearch, there are currently more than 2.5 billion people worldwide suffering from hair loss and the number has been increasing over the years, but there is a lack of effective products in the market. The board (the “**Board**”) of directors of the Company is pleased to announce that the Group has successfully developed and validated two innovative topical efficacy ingredients for hair loss prevention and hair growth, the small-molecule Remeanagen™ (XTP-118) and the peptide AquaKine™ (XTP-016), leveraging its industry leading AI molecular discovery platform. The combined formula of such “Gemini” molecules has been proven in rigorous human trials to significantly outperform existing similar products in terms of hair growth and hair loss prevention, safety, and speed of onset of action. Both molecules have successfully passed the INCI (International Nomenclature Cosmetic Ingredient) registration for new cosmetic ingredients in the U.S., and their combined formulated product, Groland, has also been approved for cosmetic product filing by the U.S. FDA (Food and Drug Administration), signifying that XtalPi’s AI platform has formally entered into the consumer healthcare sector with enormous potential. In the future, XtalPi not only focuses on drug development for fatal diseases, but also creates consumer molecular products to improve the quality of daily lives of the public.

It is XtalPi's new mission statement of "not just letting AI facilitate the R&D of every new drug, but also letting AI molecules penetrate everyone's wonderful life".

XtalPi's AI molecular platform develops innovative drug molecules to save lives, as well as safe and effective consumer product molecules to penetrate everyone's wonderful life.

About XtalPi

XtalPi was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

The Group's AI innovative R&D platform has extensive practical experience in assisting Pfizer to rapidly develop Paxlovid®, an oral COVID-19 medication; facilitating Lilly to overcome challenging drug targets; and supporting Signet to develop a breakthrough experimental molecule for diffuse gastric cancer, which was nominated for the Nobel Prize in Biomedicine — the Prix Galien Award.

By Order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao

Chairman of the Board and Executive Director

Hong Kong, 10 November 2025

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.